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Abstract
Purpose To evaluate changes in choroidal, retinal, and nerve
fiber layer (NFL) thickness following toxic anterior segment
syndrome (TASS).
Methods Macular and peripapillary choroidal thickness was
measured using enhanced depth imaging (EDI) optical coher-
ence tomography (OCT) on the day of the diagnosis and on
three follow-up exams (months 1 to 4). A similar OCT anal-
ysis of central retinal and NFL thickness was performed.
Results Thirteen TASS patients were included. Average age
was 72.8±8.7 years. Macular choroidal thickness in the supe-
rior, subfoveal, and nasal macula in the study eye was larger
than the control eye and decreased at months 2–4. This was
statistically significant only for the superior macula (p=0.004).
Peripapillary choroidal thickness was larger in the study eye at
baseline comparedwith the control eye—significantly so in the
nasal (p = 0.026) and inferior (p = 0.033) locations.
Peripapillary choroidal thickness peaked at the baseline or 1st
month exam and decreased thereafter. Retinal thickness in-
creased significantly with time, peaking at the 2nd month
and decreasing thereafter. No changes were found in the NFL.
Conclusions TASSmay have a transient effect on the choroid.
Changes in retinal thickness are probably a normal transient
postoperative response and not a result of TASS.
Keywords Choroid . Enhanced depth imaging . Optical
coherence tomography . Retina . Toxic anterior segment
syndrome
Introduction
Cataract surgery is one of the most common surgeries per-
formed worldwide, with a high rate of success. Toxic anterior
segment syndrome (TASS), a term coined by Monson et al. in
1992 [1], is a postoperative complication reported in increas-
ing numbers. It is a sterile, postoperative inflammation occur-
ring early after anterior segment surgery, generally appearing
within 12–48 h [2]. It may result in damage to various intra-
ocular tissues.
Typically, TASS presents acutely, but rarely can have a
delayed onset. Symptoms include blurry vision, discomfort,
and minimal pain. Signs include eye redness, fibrin formation
with or without hypopyon, inflammatory membranes, and
diffuse corneal edema secondary to endothelial damage. In
addition, potential damage to the iris and trabecular meshwork
may occur. The inflammation is limited to the anterior seg-
ment. TASS can present sporadically or in outbreaks [3],
possible causes are numerous [4], but in many of the cases
the cause is not identified. The outcome of topical steroidal
drops and close monitoring in the management of TASS is
excellent [5]. However, severe complications, such as irre-
versible visual loss, permanent endothelial damage, corneal
decompensation, a permanently dilated pupil, or glaucoma
due to permanent damage to the trabecular meshwork, may
occur [2, 6].
TASS has many similarities to other postoperative inflam-
matory processes, such as uveitis and endophthalmitis [7, 8].
However, it can be distinguished from endophthalmitis as it
seems to be limited to the anterior segment [2].
In the past, choroidal thickness could not be accurately
measured. Recent advancements in optical coherence tomog-
raphy (OCT) with the use of enhanced depth imaging (EDI)
allow more accurate evaluation of choroidal thickness in a
reproducible manner, as shown in previous studies [9–11]. In
the field of inflammatory eye diseases, this technique has been
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used to demonstrate changes in choroidal thickness in Vogt-
Koyanagi-Harada panuveitis subjects [12]. The inflammatory
process seen in TASS influences anterior uveal structures. Our
aim was to investigate whether these inflammatory changes
have an effect on the posterior uvea and retina and whether
subtle choroidal and retinal changes, which cannot be noticed
clinically, exist.
Materials and methods
This prospective study adhered to the tenets of the Declaration
of Helsinki and was approved by the institutional review
board (IRB) of the Tel AvivMedical Center. Informed consent
was obtained from all patients.
Participants
Thirteen eyes of 13 subjects, consecutively diagnosed with
TASS following cataract surgery, were enrolled.
A diagnosis of TASS was established based on the clinical
findings of a postoperative anterior chamber inflammatory
response with fibrin formation in either the anterior chamber,
the pupillary aperture, or just anterior to the posterior chamber
intraocular lens. All subjects had no clinical evidence of
posterior segment involvement (no vitreous inflammation
and no acute retinal findings on a dilated fundus examination).
Following a clinical diagnosis of TASS, a complete ophthal-
mological examination was performed including visual acuity
(VA), slit-lamp examination, Goldmann applanation tonome-
try, and fundus examination. In addition, a baseline spectral
domain OCT (SD-OCT) scan was performed.
Subjects underwent repeat biomicroscopic and SD-OCT
examinations, performed on month 1 (first follow-up), month
2 (second follow-up), and a final follow-up exam performed at
months 3 or 4 (third follow-up).
Spectral domain optical coherence tomography
All participants were examined using Heidelberg Spectralis
SD-OCT (Heidelberg Engineering, Heidelberg, Germany),
which achieves an axial resolution of 7 μm. The retinas of
both eyes were first scanned by a horizontal high-speed raster
scanning protocol of a 20°X20° quadrangular area, and central
macular thickness (CMT) was obtained. Glaucoma retinal
NFL protocol scan was then performed, and inferior, superior,
nasal, and temporal NFL thickness measurements were re-
corded. In addition, in order to demonstrate choroidal thick-
ness changes, EDI technique [10, 11] was used. The choroid
was scanned with 20° horizontal and vertical single cross-
section EDI scans through the center of the fovea and by a
circular EDI NFL scan protocol at the peripapilary region. To
ensure high quality and noise reduction, the eye tracking
system and averaging technique was employed. Each choroi-
dal scan consisted of 100 averaged OCT frames. Images were
converted to white on black grayscale to sharpen the contrast
and allow a more accurate measurement. Choroidal thickness
was measured by a single investigator, with an SD-OCT
software electronic caliper. Choroidal thickness was defined
as the vertical distance between the outer margin of the hyper-
reflective retinal pigment epithelium layer and the
chorioscleral interface. Choroidal thickness was measured at
five macular locations: subfoveal (an average of two
subfoveal measurements—one from the horizontal and the
other from the vertical cross-section) and 2.5 mm nasal, tem-
poral, inferior, and superior to the foveal center (Fig. 1a).
Similar measurements were performed in the peripapillary
region in four different locations: 1.75 mm superior, temporal,
inferior, and nasal to the optic disc center (Fig. 1b).
The follow-up acquisition mode, unique to this SD-OCT
device, was used in all follow-up visits and automatically
placed follow-up scans in precisely the same anatomic loca-
tion as previous scans.
Two analyses of OCT measurements were performed: The
first compared measurements of the study eye with measure-
ments of the fellow eye, while the second analysis examined
measurement changes in the study eye over time.
Choroidal thickness measurement correction
Previously published data demonstrated that choroidal thick-
ness is influenced by axial length [13]. There is an inverse
relationship between axial length and choroidal thickness.
Therefore, choroidal thickness measurements were corrected
according to the difference in axial length between the study
and fellow eye. The correction coefficient used to compensate
for axial length differences between the study and fellow eye
was based on previously published literature [14]—for every
1 mm difference in axial length, choroidal thickness was
reduced by 22 μm.
There was no need for age-related adjustments of choroidal
thickness because all comparisons were performed either in
the same eye or with the fellow eye of the same patient with no
inter-patient comparisons.
Axial length
Axial length measurements were obtained from the patient's
medical records (standard measurements performed prior to a
cataract surgery). Measurements were performed using the
IOLMaster (Carl Zeiss, Oberkochen, Germany) biometer. In
cases of media opacities, interfering with the biometer mea-
surements, axial length was measured using an A-scan 10-
MHz transducer with minimal corneal compression and with
the use of topical anesthesia. The recorded value was the mean
of six reliable measurements.
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Exclusion criteria
Exclusion criteria included cystoid macular edema of any
etiology, history of endophthalmitis or other infectious pro-
cess in the study eye, history of idiopathic or autoimmune-
associated uveitis in either eye, history of any posterior seg-
ment operation prior to the cataract procedure in either eye,
any procedure, but for uneventful cataract surgery, patients
receiving steroidal treatment (systemic or topical) prior to the
cataract surgery, and media opacities preventing OCT imaging
of the retina or choroid.
Statistical analysis
Data was recorded using Microsoft Excel and analyzed using
SPSS version 21 (SPSS Inc., Chicago, IL, USA). Because of
the small sample size, non-parametric tests were used. The
Friedman test was used to compare overall difference in
measurements over time (including baseline exam and the
three follow-up exams) or difference between the choroidal
thickness measurement locations.
Pairwise comparison of two time-point or measurement
locations was analyzed by the Wilcoxon Matched-Pairs
Signed-Ranks Test. All tests were two-tailed, and the thresh-
old for statistical significance was defined as a p value <0.05.
Results
Patients and procedures
Thirteen participants were included in the study—nine wom-
en and four men. The average age was 72.8±8.7 years (range
57–89 years). There were three left study eyes and 10 right
study eyes. Two patients had bilateral epiretinal membrane
with no evidence of macular edema, and one patient had a
history of branch retinal vein occlusion in his control eye with
no evidence of macular edema prior to or following surgery.
All patients had undergone uneventful cataract extraction
surgeries.
Twelve of 13 patients had normal findings at the routine 1-
day postoperative exam and have been diagnosed with TASS
at the routine 1-week postoperative exam (mean 8.1 days).
They did not seek earlier ophthalmologic consult prior to the
routine 1-week exam. One patient presented at the clinic
3 days following surgery, with TASS-related complaints and
was then diagnosed. All TASS cases resolved under topical
steroidal treatment (in 10 of 13 eyes, a mydriatic agent was
also administered). One patient had residual posterior iris
synechiae, one patient developed pseudophakic CME (diag-
nosed 8 weeks following TASS diagnosis), and a third patient
had both residual synechiae and mild pseudophakic CME
(diagnosed 10weeks following TASS diagnosis). The remain-
ing 10 patients had no stigmata following TASS resolution.
Average follow-up times (post TASS diagnosis) for the first,
second, and third follow-up exams were: day 10.5±5.6, day
35±7.7, and day 95.2±23.8, accordingly. Follow-up exams
included clinical evaluation and OCT exams.
Macular choroidal thickness measurements
Mean macular choroidal thickness±SD at the subfoveal, su-
perior, temporal, inferior, and nasal locations was 260±84,
248±77, 219±57, 197±65, and 158±75 μm, respectively. All
differences in macular choroidal thickness were statistically
significant, except for the difference between superior and
subfoveal measurements (p=0.604) (Table 1).
Macular choroidal thickness measurements are shown in
Table 2. Superior macular choroidal thickness in the study eye
was significantly larger at baseline and 1st month exams (276
Fig. 1 a. (Patient 13) A left eye infrared map of enhanced depth imaging
(EDI) optical coherence tomography (OCT) foveal measurement
locations (red circles) at the foveal center and 2.5 mm nasal, temporal,
inferior, and superior to the foveal center. The yellow lines represent the
OCT cross-sections. b. (Patient 1) A right eye infrared map of EDI-OCT
peripapillary measurement locations (red circles) 1.75 mm nasal,
temporal, inferior, and superior to the optic disc center. The yellow-green
circle represents the OCT cross-section
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±74 and 276±84 μm, respectively) when compared with the
control eye (213±82 μm) (p=0.004 and p=0.028, respective-
ly). Thickness significantly decreased at the 2nd month and
3rd/4th month follow-up exams to 266±79 and 231±40 μm,
respectively (compared with baseline thickness in the study
eye (p=0.018 and p=0.017, respectively) (Fig. 2a).
Subfoveal and nasal macular choroidal thickness increased
at baseline and 1st month exams and decreased at the 2nd and
3rd/4th month exams. These differences were not statistically
significant (both for comparison with the control eye and
comparison with baseline thickness in the study eye). Only
one significant difference was shown in nasal choroidal thick-
ness between study and controls eye at the 2nd month exam
(see Fig. 2b and c). No specific pattern was shown in temporal
and inferior macular thickness (see Fig. 2d and e).
Peripapillary choroidal thickness measurements
Mean peripapillary choroidal thickness±SD at the superior,
temporal, nasal, and inferior locations was 181±63, 170±74,
150±,60 and 128±53 μm, respectively. All differences be-
tween peripapillary choroidal thickness locations were statis-
tically significant (p<0.001), except for the difference be-
tween temporal and nasal measurements (p=0.081).
Table 1 Macular Choroidal Thickness Differences (p-values shown)
p-Value Subfoveal Superior Temporal Inferior
Superior 0.604 – – –
Temporal 0.003 0.022 – –
Inferior <0.001 <0.001 0.007 –
Nasal <0.001 <0.001 <0.001 <0.001
Table 2 Macular Choroidal Thickness Changes
Measured Location Mean (μm) STDa (μm) p-Value
Compared with Control Eye Compared with Study Eye Baseline
Subfoveal Control (Fellow) Eye 263.04 87.79 – –
Study Eye Baseline b 264.83 84.47 0.638 –
Month 1 293.93 94.82 0.612 0.395
Month 2 262.78 84.51 0.515 0.058
Months 3-4 220.25 47.79 0.508 0.373
Nasal Control (Fellow) Eye 141.92 62.75 – –
Study Eye Baseline b 166.33 80.68 0.347 –
Month 1 195.14 87.20 0.128 0.271
Month 2 159.56 79.74 0.038* 0.735
Months 3-4 142.64 54.47 0.424 0.575
Superior Control (Fellow) Eye 212.54 81.61 – –
Study Eye Baseline b 275.73 74.20 0.004* –
Month 1 276.14 84.45 0.028* 0.398
Month 2 265.63 79.33 0.123 0.018*
Months 3-4 230.83 40.08 0.110 0.017*
Temporal Control (Fellow) Eye 232.85 59.60 – –
Study Eye Baseline b 227.09 50.63 0.722 –
Month 1 216.86 53.56 0.735 0.753
Month 2 221.67 71.48 0.314 0.398
Months 3-4 201.00 52.32 0.022* 0.093
Inferior Control (Fellow) Eye 186.40 77.23 – –
Study Eye Baseline b 206.83 56.93 0.158 –
Month 1 193.14 66.50 0.237 0.612
Month 2 192.33 66.35 0.214 0.028*
Months 3-4 192.10 58.06 0.241 0.327
a STD = Standard Deviation
b Baseline = Measurement on the day of TASS diagnosis
* Statistically Significant
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Peripapillary choroidal thickness measurements are shown
in Table 3. Superior, temporal, nasal, and inferior baseline
thickness in the study eye were 187±61, 183±84, 166±71,
and 149±61 μm, respectively. These were larger than control
eye measurements which were 180±66, 151±63, 143±56,
and 116±59 μm, respectively. The differences were
Fig. 2 Macular choroidal
thickness measurements (a
Superior, b Subfoveal, c Nasal, d
Temporal, e Inferior). Only
significant p-values are shown.
p1, p-value for comparison with
baseline measurements in the
study eye. p2, p-value for
comparison with fellow eye
measurements
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statistically significant for the nasal (p=0.026) and inferior
(p=0.033) locations. In the superior (187±61 μm) and nasal
(166±71 μm) locations maximal thickness was at the base-
line exam. In the temporal (183±84 μm) and inferior (149±
61 μm) locations maximal thickness was at the 1st month
exam. These differences were not statistically significant
(Table 3). Peripapillary thickness decreased thereafter
(Fig. 3). Differences were not statistically significant when
compared with baseline measurements in the study eye
(Table 3).
Table 3 Peripapillary Choroidal Thickness Changes
Measured Location Mean (μm) STDa (μm) p-Value
Compared with Control Eye Compared with Study Eye Baseline
Inferior Control (Fellow) Eye 116.19 58.66 – –
Study Eye Baseline b 149.36 60.74 0.033* –
Month 1 133.50 54.66 0.133 0.058
Month 2 115.00 49.62 0.917 0.144
Months 3-4 128.80 55.38 0.285 0.173
Nasal Control (Fellow) Eye 142.94 56.41 – –
Study Eye Baseline b 165.55 71.22 0.026* –
Month 1 159.08 68.74 0.046* 0.833
Month 2 124.50 49.40 0.917 0.273
Months 3-4 151.20 70.69 0.508 0.066
Superior Control (Fellow) Eye 180.03 66.11 – –
Study Eye Baseline b 186.82 60.63 0.790 –
Month 1 222.40 42.40 0.345 0.891
Month 2 158.67 78.07 0.917 0.080
Months 3-4 175.35 60.25 0.959 0.779
Temporal Control (Fellow) Eye 151.65 62.53 – –
Study Eye Baseline b 182.60 84.15 0.386 –
Month 1 199.50 107.75 0.249 0.414
Month 2 179.67 89.20 0.028* 0.500
Months 3-4 143.55 44.06 0.959 0.726
a STD = Standard Deviation
b Baseline = Measurement on the day of TASS diagnosis
* Statistically Significant
Fig. 3 Peripapillary choroidal
thickness measurements
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Central retinal thickness and nerve fiber layer measurements
Mean CMTat baseline was 288±48μm, compared with 271±
38 μm in the control (fellow) eye. This difference of 17 μm
was not statistically significant (p=0.382). Changes in CMTat
the 1st, 2nd, and 3rd/4th month exams are shown in Fig. 4.
Difference in CMT between the study and control eyes was
statistically significant only at the 2nd month exam (a differ-
ence of 44.2 μm, p=0.036) (Fig. 4).
Peripapillary NFL thickness did not change significantly in
any location and showed no specific pattern (Table 4).
Discussion
In this study, we evaluated quantitatively possible changes in
choroidal, retinal, and nerve fiber layer thickness following an
occurrence of TASS. Few studies have used EDI-OCT to
evaluate inflammatory-related changes in choroidal thickness.
Published studies evaluated diseases with a known
chorioretinal involvement, such as Vogt-Koyanagi-Harada
[12, 15]. and Multiple Evanescent White Dot Syndrome
(MEWDS) [16]. We attempted to discover subtle inflamma-
tory changes in the choroid, resulting from an acute anterior
segment inflammatory process, with no clinical evidence of
posterior segment involvement.
Macular choroidal thickness in the superior, subfoveal, and
nasal macula did increase and was larger than the fellow eye.
This was statistically significant only for the superior macula.
Peripapillary choroidal thickness was larger in the study eye at
baseline compared with the control eye. This difference was
statistically significant for the nasal (p=0.026) and inferior
(p=0.033) locations. There appeared to be a pattern in all
peripapillary choroidal locations, showing a peak thickness
at the baseline or 1st month exam with a decrease thereafter.
However, these changes were not statistically significant.
There are no previous publications examining choroidal
thickness changes following TASS. Two recent publications
examined changes in subfoveal choroidal thickness follow-
ing uneventful cataract extraction and had conflicting re-
sults. The first paper found a significant increase in
subfoveal choroidal thickness following cataract surgery in
Fig. 4 Central macular thickness
difference from control (fellow)
eye. *Significant p-values;
p-values are for comparison with
fellow eye measurements
Table 4 Nerve fiber layer thickness changes
Location Mean (μm) STDa (μm) p-Value*
Nasal Baseline b 88.18 34.19 –
Month 1 92.50 45.11 0.246
Month 2 79.30 11.79 0.893
Months 3-4 92.70 39.80 0.573
Superior Baseline b 124.36 34.40 –
Month 1 122.42 38.00 0.753
Month 2 114.33 38.72 0.138
Months 3-4 123.15 24.39 0.086
Temporal Baseline b 71.09 17.68 –
Month 1 73.92 22.32 0.596
Month 2 70.50 16.02 0.715
Months 3-4 67.30 12.07 0.528
Inferior Baseline b 123.00 30.11 –
Month 1 107.17 22.73 0.600
Month 2 118.67 31.77 0.686
Months 3-4 128.80 20.16 0.141
a STD = Standard Deviation
b Baseline=Measurement on the day of TASS diagnosis
* p-Values represent comparisons with Baseline measurements
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29 patients [17]. The second paper analyzed both subfoveal
and peripapillary choroidal thickness measurements and
found no significant change following cataract extraction
[18]. Therefore, the trend found in our study may be
attributed to the TASS, but evidence in the literature regard-
ing choroidal changes following cataract extraction are
inconclusive.
We also observed constant significant differences in cho-
roidal thickness between different measurement locations. In
the macular region, thickness ratio was subfoveal>superior>
temporal>inferior>nasal (260±84, 248±77, 219±57, 197±
65, and 158±75 μm, respectively). These differences are
consistent with previously published data and include nasal
macular choroid is the thinnest [10, 19], superior macular
choroid is thicker than inferior macular choroid [13, 14],
subfoveal choroid is thicker than either nasal or temporal
macular choroid [11,14,19]. Also, mean subfoveal choroidal
thickness in our study (260±84 μm) is similar to the value
found in a recently published, large population-based study,
performed on 3,233 subjects (254±107 μm) [20]. In the
peripapillary region, thickness ratio was superior>tempo-
ral>nasal>inferior (181±63, 170±74, 150±60, and 128±
53 μm, respectively). Previous literature shows that superior
peripapillary choroid is thicker than inferior peripapillary
choroid [21–23]. The correlation of our findings with previ-
ously published data strengthens the validity of our measure-
ments and vice versa.
Measurements of retinal CMTshowed an increase in retinal
thickness, peaking at the 2nd month (statistically significant)
and decreasing thereafter. The changes can be attributed to a
transient subclinical macular inflammatory response to the
cataract procedure and not to the TASS itself. Such changes
following cataract surgery have been previously demonstrated
in the literature [18, 24, 25]. Two patients developed CME
during follow-up. In both cases, CME was not evident at the
2nd month follow-up and appeared later. Therefore, it did not
seem to be a major contributor to the peak CMT change seen
at month 2. No significant change in NFL thickness was
observed.
In conclusion, TASS may have a transient effect on the
choroid. Retinal changes observed may be related to the
cataract procedure itself as previously described.We acknowl-
edge some limitations of the study, which include a small
sample size and a lack of OCT measurements prior to the
occurrence of TASS. Choroidal measurements were corrected
for inter-eye axial length differences, but compensating for the
known diurnal variation in choroidal thickness [26, 27] was
not feasible in the outpatient clinic setting.
The novel use of EDI-OCT enabled accurate imaging and
quantification of choroidal changes. This study demonstrated
that a significant inflammatory reaction involving the anterior
uvea, such as TASS, might also have an effect on the posterior
uvea. Further studies are needed to corroborate this. The
continued use of EDI-OCT will help prove or refute theories
of choroidal involvement in different pathologies and provide
better understanding of disease processes and etiologies.
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